Artivion, Inc. (NYSE:AORT) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. trimmed its position in shares of Artivion, Inc. (NYSE:AORT) by 7.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,065 shares of the company’s stock after selling 1,642 shares during the quarter. Corebridge Financial Inc.’s holdings in Artivion were worth $602,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Quarry LP increased its holdings in Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after acquiring an additional 786 shares during the period. R Squared Ltd purchased a new position in shares of Artivion in the 4th quarter valued at about $39,000. Arcadia Investment Management Corp MI purchased a new position in shares of Artivion in the 4th quarter valued at about $43,000. Finally, Venturi Wealth Management LLC acquired a new position in Artivion in the 4th quarter worth about $78,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on AORT shares. JMP Securities restated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Finally, Stifel Nicolaus decreased their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.40.

Artivion Stock Performance

Shares of NYSE:AORT opened at $23.05 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a 1 year low of $19.36 and a 1 year high of $32.33. The firm has a market capitalization of $969.16 million, a PE ratio of -1,152.45 and a beta of 1.65. The business’s 50 day moving average price is $26.78 and its 200-day moving average price is $27.61.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the sale, the senior vice president now directly owns 149,799 shares in the company, valued at approximately $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Lance A. Berry sold 3,259 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $89,003.29. Following the completion of the transaction, the chief financial officer now owns 75,805 shares in the company, valued at $2,070,234.55. The trade was a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,799 shares of company stock valued at $2,356,223. Corporate insiders own 8.10% of the company’s stock.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.